Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT05236517
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT05232708
- Locations
- 🇬🇧
Parexel CPRU, Level 7, Harrow, Middlesex, United Kingdom
Awareness, Care & Treatment In Obesity Management - An Observation in Switzerland
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1152
- Registration Number
- NCT05232786
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 458
- Registration Number
- NCT05230615
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Sesto San Giovanni, Italy
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT05230550
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT05230589
- Locations
- 🇸🇦
Specialized Medical Cente, Riyadh, Saudi Arabia
🇸🇦Master Centre for Saudi, Riyadh, Saudi Arabia
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 546
- Registration Number
- NCT05227196
- Locations
- 🇺🇸
Altasciences Clinical LA, Inc., Cypress, California, United States
🇺🇸Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
🇨🇦Altasciences Company Inc., Montreal, Quebec, Canada
China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 887
- Registration Number
- NCT05221580
- Locations
- 🇨🇳
NIS-The First People's Hospital of Yulin City, Yulin, Guangxi, China
🇨🇳NIS-Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳NIS-Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12
- Registration Number
- NCT05178550
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT05153564
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany